ArticleBMC gastroenterology2026
The efficacy and safety of endoscopic ultrasound selective variceal devascularization for the treatment of esophagogastric varices: a retrospective cohort study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundGastroesophageal variceal bleeding is a life-threatening complication of portal hypertension. This study evaluated the efficacy and safety of endoscopic ultrasound-guided selective variceal devascularization (EUS-SVD) compared with conventional endoscopic cyanoacrylate injection.
methodsThis retrospective cohort study adhered to the STROBE guidelines. Between August 2022 and June 2024, 107 patients were enrolled and allocated to conventional endoscopy (n = 52) or EUS-SVD (n = 55). Propensity score matching was performed to reduce confounding. Primary outcomes included rebleeding, ulcer formation, and resource utilization.
resultsCompared with the conventional group, the EUS group required significantly lower volumes of polidocanol and cyanoacrylate (both P < 0.05). The 6‑month rebleeding rate and 3‑month ulcer formation rate were significantly lower in the EUS group (P < 0.05). Kaplan-Meier analysis demonstrated a reduced cumulative rebleeding incidence in the EUS group (HR 0.38, 95%CI 0.17-0.86, P = 0.021).
conclusionsWithin the limitations of a single-center retrospective design, these findings suggest that EUS-SVD may represent a promising therapeutic option for gastroesophageal varices, although it requires validation in prospective randomized trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.